Don’t bury Cassava’s promising Alzheimer’s drug
Автор: Matthew Nachtrab
Загружено: 2022-07-29
Просмотров: 1720
Описание:
Background: Cassava Sciences has worker for 12 years to research a drug to help patients with Alzheimer's. They collaborated with Hoau-Yan Wang, a Neurology researcher and professor from CUNY. They discovered a drug, Simufilam, that has shown promising treatment effects and strong safetly profile in phase 1 and 2. The recieved FDA approval with for 2 phase 3 trials with Special Protocol Assessments in August of 2021. Right before the agreement short sellers trying to reduce their stock price began executing a major attack on the credibility of the company. Those attacks have resulted in the stock declining from $140 to $15. They made complaints to the DOJ, FDA, SEC, and NIH. The FDA complaint was in the form of a Citizens Petition to halt the approved FDA trails. The FDA denied the petition. Now the drug is in phase 3 trials at 140 clinical sites. Over 500 patients are taking the medicine and there have been ZERO drug related safety events from Simufilam. What makes me so confused about the whole situation is why not just let the trial run and allow them to show if it works or not?
This is a clip from the following original full video.
• Cassava Sciences faces criminal probe tied...
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
